pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

493 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1157Endpoints875BioPharma Dive339BioSpace298Fierce Biotech277onclive165raps104globenewswire health73
therapy area
allOncology7399Rare Disease1831Cardiology1673Immunology1467Hematology1302Vaccines1181Pulmonology1088Psychiatry & CNS860
  • FDA clears Dexcom's Stelo as first OTC continuous glucose monitor for children
    The U.S. Food and Drug Administration cleared Dexcom's Stelo Glucose Biosensor System for over-the-counter use in children two years of age and older who do not use insulin. This is the first OTC…
    fda press · 2mo agoApprovalPositive↗ source
  • Prometheus secures $12 billion to develop artificial general engineers as biotech deals surge
    Prometheus announced a $12 billion capital raise aimed at building what it calls “artificial general engineers,” a new class of AI tools for biopharma research and development. Nonprofit Blood Can…
    STAT · 2mo agoDealPositive↗ source
← prev
page 13 of 20
next →
fda medwatch65
fda recalls62
fda press38
Ophthalmology492
Pain470
Endocrinology & Metabolism466
Infectious Disease439
  • Blood Cancer United acquires remaining supply of discontinued investigational drug Luvelta
    Blood Cancer United, a nonprofit focused on blood cancers, is purchasing the remaining inventory of Luvelta, an investigational cancer drug that has been discontinued. The acquisition aims to pres…
    STAT · 2mo agoNeutral↗ source
  • J&J reports positive Phase 2/3 results for Imaavy in rare autoimmune anemia, paving way for label expansion
    Johnson & Johnson announced that its drug Imaavy, already approved for myasthenia gravis, produced durable hemoglobin improvements in a Phase 2/3 trial for warm autoimmune hemolytic anemia, a rare…
    BioPharma Dive · 2mo agoPositive readoutPositive↗ source
  • Long Covid research faces funding cut as NIH terminates grant, highlighting political neglect
    Steven Phillips, a science strategist at the COVID Collaborative, notes that a two‑year study of long Covid’s impact on the nervous system was halted when the NIH withdrew its RECOVER grant, labeli…
    STAT · 2mo agoNegative↗ source
  • AMA and lawmakers challenge insurer AI denial practices, call for oversight
    The American Medical Association and several members of Congress are publicly opposing recent denials of care that rely on artificial‑intelligence algorithms used by insurers. The Department of He…
    STAT · 2mo agoRegulatoryNeutral↗ source
  • Nonprofit Blood Cancer United purchases remaining Luvelta supplies to keep compassionate access for children
    Blood Cancer United, formerly the Leukemia & Lymphoma Society, announced it will purchase the remaining inventory of Luvelta, an investigational antibody‑drug conjugate that had been discontinued.…
    STAT · 2mo agoDealPositive↗ source
  • Study finds socioeconomic status drives brain development differences in 9- and 10-year-olds
    Researchers at Washington University School of Medicine examined brain MRI scans from almost 12,000 children who were nine or ten years old. The analysis showed that a child's socioeconomic backgr…
    STAT · 2mo agoNeutral↗ source
  • AstraZeneca advances obesity pill to Phase 3 after mid-stage trials show ~11% weight loss
    AstraZeneca announced that its experimental oral GLP-1 drug, elecoglipron, will enter an extensive Phase 3 development program following encouraging data from two mid-stage studies in obesity and d…
    BioPharma Dive · 2mo agoPositive readoutPositive↗ source
  • GSK to acquire Nuvalent for $10.6 billion, expanding its lung-cancer pipeline
    GSK announced it will buy Cambridge-based biotech Nuvalent for $10.6 billion, paying $124 per share, a 26% premium to the biotech's recent average share price. Nuvalent has two lung‑cancer drugs u…
    STAT · 3mo agoDealNeutral↗ source
  • Dexcom trial shows continuous glucose monitors improve outcomes across diabetes types
    Dexcom reported results from a randomized controlled trial that evaluated its continuous glucose monitoring system in a wide range of people with diabetes. The study compared the CGM device to stan…
    STAT · 3mo agoPositive readoutPositive↗ source
  • Trump administration threatens fines for over 500 hospitals that fail to disclose pricing
    The Trump administration has warned more than 500 hospitals that they are not providing the public with basic pricing information, the Associated Press reported. Hospitals that fail to create a pl…
    STAT · 3mo agoRegulatoryNegative↗ source
  • Roche commits $700 million to co-develop Nurix's BTK-degrading drug bexobrutideg
    Roche announced a partnership with Nurix Therapeutics to co-develop a protein-degrading therapy called bexobrutideg, which targets the BTK enzyme. Under the agreement, Roche will pay $700 million…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • Lilly shares safety data on next-gen obesity drug retatrutide; Revolution Medicines reports strong pancreatic cancer results
    Lilly provided new data that detail the safety and tolerability profile of its next-generation obesity therapy, retatrutide. The information adds to the growing body of evidence supporting the drug…
    STAT · 3mo agoPositive readoutPositive↗ source
  • AstraZeneca’s oral GLP-1 candidate elecoglipron cuts weight 11% in Phase 2 obesity trial
    A Phase 2 study (VISTA) of AstraZeneca’s oral GLP‑1 molecule elecoglipron in people with obesity showed an average weight loss of 11.2 % after 36 weeks, according to data presented at the American…
    STAT · 3mo agoPositive readoutPositive↗ source
  • Incyte to acquire Vega Therapeutics for up to $2 billion, securing late-stage von Willebrand disease drug
    Incyte announced it will purchase Vega Therapeutics, a unit of Star Therapeutics, for $1.25 billion in cash with the possibility of receiving up to $750 million more if future sales targets are met…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • Congo Ebola frontline health workers face low pay and exhaustion amid outbreak
    Dr. Richard Lokudu, medical director of Mongbwalu General Referral Hospital, says he and his colleagues are receiving almost no compensation while treating patients in the current Ebola outbreak.…
    STAT · 3mo agoNegative↗ source
  • City Therapeutics secures $99.5 million to advance RNAi drugs targeting clotting disorder and Stargardt disease
    City Therapeutics, a young biotech focused on RNA interference therapies, announced it has raised $99.5 million to support further development of its pipeline. The funding will back its lead candid…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • Incyte CEO frames $2 billion Vega acquisition as key to post-Jakafi strategy
    Incyte's chief executive Bill Meury said the company’s recent $2 billion purchase of Vega is intended to expand its blood‑disorder pipeline beyond the already‑approved Jakafi. Meury, who has previ…
    Endpoints · 3mo agoDealPositive↗ source
  • Novo downplays contested obesity drug as rivals report promising cancer combos and Incyte makes $2 billion blood-disease acquisition
    Novo executives said the obesity drug they once fought Pfizer for is less impressive than expected, downplaying its potential. Revolution Medicines and Tango Therapeutics reported a high response…
    STAT · 3mo agoNeutral↗ source
  • Mass General launches mobile vascular clinic to treat unhoused patients and prevent amputations
    Unhoused individuals often face untreated vascular problems that can quickly lead to severe wounds and the risk of losing a limb. Limited access to regular medical care leaves many without timely i…
    STAT · 3mo agoPositive↗ source
  • Lilly presents safety data on obesity drug retatrutide, noting rare cardiac events
    Eli Lilly reported new safety and tolerability findings for its next-generation obesity therapy retatrutide at the American Diabetes Association annual meeting. In the study, 7 of the 403 particip…
    STAT · 3mo agoNegative readoutNeutral↗ source
  • Growing Amish population poses unique public health challenges, says STAT opinion piece
    The First Opinion podcast explored how the expanding Amish community impacts public health, noting that the group may approach 2 million people in the United States by 2075. While some political fi…
    STAT · 3mo agoNeutral↗ source
  • Lundbeck advances PACAP-targeting migraine drug after mid-stage trial shows reduction in migraine days
    Lundbeck reported new data from a mid-stage study of its experimental migraine prevention therapy, bocunebart, which targets the PACAP protein involved in headache pathways. The trial enrolled hun…
    BioPharma Dive · 3mo agoPositive readoutPositive↗ source
  • CDC warns Ebola could swell to 20,000 cases in Central Africa without rapid containment
    The U.S. Centers for Disease Control and Prevention released a new analysis indicating that the Ebola outbreak in Central Africa could expand to as many as 20,000 cases if infected individuals are…
    STAT · 3mo agoNegative↗ source